Retatrutide · 60 mg
Published- batch · LOT
- B-2026-RETA-60-002
- Laboratory
- Testides
- purity
- 99.94%
- Test date
- 16.07.2026
Analytics cookies help us understand what works in the catalog. Accept all, reject non-essential ones, or choose categories below. Privacy policy
An experimental weight-control peptide: acts on three hormones — GIP, GLP-1 and glucagon, injected once a week. In phase 2, weight loss kept growing through all 48 weeks of the study; it is not approved by any regulator yet.
Selected size: 5 mg
60 mg analysis published
Research, properties and limitations
AI can make mistakes
Titration schedule · reference
The information below is provided from public sources for reference only. It is not advice or instructions for use; products are intended for laboratory research only and not for human consumption.
| Period / condition | Dose | Escalation |
|---|---|---|
| Start (weeks 1–4) | 2.5 mg once weekly subcutaneously | Starting dose |
| Titration (every 4 weeks) | 5 → 10 mg once weekly | Increase if needed |
| Upper bound of this schedule | 15 mg once weekly | Maximum in this schedule |
Research overview · reference
Below is a short summary of what the authors of published studies reported. It is not medical advice or instructions for use; products are intended for laboratory research only and not for human consumption.
| Effect | Model or participants | How often or as described | Source |
|---|---|---|---|
| Diarrhea | TRIUMPH-2: adults with obesity and type 2 diabetes, 80 weeks, versus placebo | 27% (4 mg), 34% (9 mg), 34% (12 mg) vs 13% with placebo | [3] |
| Nausea | TRIUMPH-2 | 14% (4 mg), 21% (9 mg), 28% (12 mg) vs 8% with placebo | [3] |
| Hypotension | TRIUMPH-2 | 1% (4 mg), 5% (9 mg), 6% (12 mg) vs under 1% with placebo | [3] |
FAQ
Find answers to questions about Retatrutide and related materials.
It is an experimental weight-control peptide that acts on three hormones at once: GIP and GLP-1 handle fullness and blood sugar, while glucagon speeds up energy expenditure. It is being studied for obesity and type 2 diabetes. It is injected once a week.
Source / documentationThe powder is dissolved with bacteriostatic water and injected under the skin once a week. In studies, people started at 2.5 mg and raised the dose every 4 weeks; the working doses in phase 2 were 4, 8 and 12 mg. The dose is raised slowly because stomach side effects depend on the speed of escalation. The full schedule is in the dosing guide on this page.
Source / documentationNo, retatrutide is not approved by the FDA or the EMA yet: phase 3 studies are under way, and no finished retatrutide medicine exists anywhere. Nobody has announced an exact launch date — it depends on the phase 3 results and the regulators' decision.
Source / documentationRetatrutide acts on three receptors, tirzepatide on two, and in phase 2 retatrutide showed very strong weight loss. But the comparison needs care: tirzepatide is an approved drug with completed large studies, while retatrutide is still experimental and its long-term profile is still being studied.
Source / documentationThe most common are gastrointestinal: nausea, diarrhea, vomiting and constipation. In the studies they clearly depended on the dose and the speed of escalation — which is why the dose is raised slowly, one step every 4 weeks. A detailed breakdown is in our retatrutide study review and its wiki monograph.
Source / documentationSemaglutide copies one hormone — GLP-1 — while retatrutide acts on three receptors: GIP, GLP-1 and glucagon. Semaglutide is an approved, long-studied drug; retatrutide is an experimental molecule that produced stronger weight loss in phase 2 but has not completed phase 3 yet.
Source / documentationKeep the dry powder in a dry, dark place at a low temperature. Once dissolved, store it in the refrigerator and do not freeze it again. Details are in the batch documentation on this page.
Source / documentationYou can buy retatrutide right on this page of our store: the current price and stock are shown in the product card. We deliver across Ukraine with Nova Poshta — to a branch, a parcel locker, or by courier. Payment is by card, by crypto (with a 5% discount), or on delivery. Every vial ships with the certificate of analysis (COA) for its exact batch.
Source / documentationLet the vial warm to room temperature, then slowly add bacteriostatic water with a syringe down the vial wall. Swirl the vial gently in your hands until the powder dissolves; never shake it. The amount of water depends on the vial size and the concentration you need — a worked example for your schedule is in the preparation guide on this page.
Source / documentationIn phase 2 the course lasted 48 weeks, and weight loss was still continuing at the very end of the study. On safety, honestly: the drug is experimental, and phase 3 is still collecting the long-term data. What is known — the most common side effects are gastrointestinal (nausea, diarrhea), and they depend on the dose and how fast it is raised.
Source / documentationThe half-life of retatrutide is approximately 6 days by subcutaneous administration, from the phase 1b study (Lancet). Retatrutide is investigational — no approved FDA/EMA label exists, so the half-life is known from clinical publications rather than a regulatory document. See the Dosing section for detail.
Source / documentationCertificates shown: 1
Share your experience
No reviews yet. Tell others what you think of this product.
Retatrutide is an experimental weight-control peptide that acts on three hormones at once. Semaglutide copies one hormone (GLP-1), tirzepatide copies two (GIP and GLP-1), and retatrutide adds a third — glucagon. GLP-1 and GIP handle fullness and blood sugar, while glucagon speeds up energy expenditure: the body not only eats less, it also burns more. It is injected once a week and stays in the body for about 6 days.
What the studies showed: in phase 2, higher doses produced greater weight loss than lower ones, and the effect kept growing out to 48 weeks. The full breakdown is in our review of the retatrutide studies. Important: the drug is not approved by any regulator yet (neither FDA nor EMA) — phase 3 is under way, and no finished retatrutide medicine exists anywhere.
How it is used in studies: the powder is dissolved with bacteriostatic water and injected under the skin once a week. You start at 2.5 mg and raise the dose every 4 weeks — in phase 2 the working doses were 4, 8 and 12 mg. The slow ramp-up matters because stomach side effects depend on the dose and the speed of escalation. The exact schedule is in the dosing guide on this page.
Batch and analysis: find the LOT number on your vial label and match it against the report in our COA archive. The report confirms the batch analytics at the time of testing.
Comparison: how the neighbours in this class work is covered in our wiki monographs — semaglutide (one receptor), tirzepatide (two receptors) and liraglutide (daily). The full line is in the GLP-1 peptides category on the site.
Documentation and storage: the form is a dry powder (lyophilisate). Storage, dissolution and handling are described in the batch documentation: dry powder in a dry, dark place at a low temperature; once dissolved, in the refrigerator. The scientific details — mechanism and structure — are in the retatrutide monograph in our wiki.
Buy 2, get the 3rd free
The set contains two vials of 60 mg.
120 mg: Best value · Save ≈ $58.09